Clinical Trials Logo

Brain Aneurysms clinical trials

View clinical trials related to Brain Aneurysms.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02381522 Completed - Brain Aneurysms Clinical Trials

Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage

RIPC-SAH
Start date: March 1, 2015
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate if briefly stopping blood flow to the patient's leg will lead to the patient's body being better able to tolerate possible decreased blood flow to regions of the brain which otherwise frequently happens after subarachnoid hemorrhage. Previous studies show that various organs such as the heart, brain or kidney can tolerate longer periods of decreased blood flow if prior to that insult shorter periods of decreased blood flow were experienced.

NCT ID: NCT01558102 Completed - Brain Aneurysms Clinical Trials

International Retrospective Study of Pipeline Embolization Device

IntrePED
Start date: March 2012
Phase: N/A
Study type: Observational

The primary objective of this retrospective study is to determine the incidence of important safety outcomes in patients who have undergone Pipeline Embolization Device placement for intracranial aneurysms (IAs). This study does not effect patient care, simply it is designed to observe and capture information from numerous hospitals. Data collection will be initiated starting March 2012 and continue until approximately April 2017.

NCT ID: NCT00783523 Completed - Clinical trials for Arteriovenous Malformations

Influence of MMP on Brain AVM Hemorrhage

Start date: March 2008
Phase: Phase 1
Study type: Interventional

Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology and pathogenesis are unknown. There is no medical therapy presently available. Prevention of spontaneous intracerebral hemorrhage (ICH) is the primary reason to treat brain vascular malformations. The goal of this study is to: begin pilot studies to lay the groundwork for future clinical trials to develop medical therapy to decrease ICH risk. Matrix metalloproteinases (MMPs) regulate the extracellular matrix in association with various hemorrhagic brain disorders. MMP-9 has been most consistently associated with vascular wall instability and hemorrhagic brain disorders. Doxycycline, a non-specific MMP inhibitor, may enhance vascular stability, thus reducing the risk of spontaneous hemorrhage in brain vascular malformations by decreasing MMP-9 activity.